Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012

Five Star Equities Provides Stock Research on Acura Pharmaceuticals and DARA Biosciences

Marketwired

NEW YORK, NY--(Marketwire - Nov 30, 2012) - The Biotech Industry has skyrocketed in 2012 as an increase in the number of new drug approvals has boosted investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) and the SPDR S&P Biotech ETF (XBI) have both gained over 25 percent year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and DARA Biosciences Inc. (NASDAQ: DARA).

Access to the full company reports can be found at:

www.FiveStarEquities.com/ACUR

www.FiveStarEquities.com/DARA

"In 2011, the U.S. FDA approved 30 new drugs, compared to 21 in 2010," S&P Capital IQ wrote in a note. "Through September 2012, the year-to-date total was 22. We see an improving trend for FDA first cycle review approvals and a rise in the rate of new drug approvals for rare diseases, which we think is helping to boost investor sentiment for the agency, after years of criticism stemming from inconsistency in making and communicating its decisions."

Another key factor in the Biotech Industry's success has been the "patent cliff" major pharmaceuticals have faced in 2012. Major drug manufacturers have looked to biotech companies to help offset major revenue losses from expiring patents as it is less time consuming than developing new drugs through R&D.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Acura Pharmaceuticals has recently reported topline results from a clinical study of NEXAFED. "It is important that our IMPEDE technology used in NEXAFED does not compromise the effectiveness of the active ingredient, and the results of our clinical study demonstrate this," said Bob Jones, President and CEO of Acura Pharmaceuticals. "We remain on track for a national launch of NEXAFED later this year."

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. Shares of the company surged Thursday after reporting that it has submitted an Orphan Drug Application to the FDA for KRN5500, a treatment for chronic chemotherapy-induced peripheral neuropathy.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.FiveStarEquities.com/disclaimer

Contact:

Five Star Equities
Email Contact
View Comments (0)